Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hate to be a pessimist. I hope RootsRX goes through but I dont feel like it will. The agreement was for $15M cash ($7.5M) and stock (~1.8M)...with the stock price at $2.95 (that's like 4,425,000 shares at a value of $1.20). Thirty percent of the cash payment ($2.25M) was deferred 1 year after close.
Here is hoping that RootsRX was willing to renegotiate. The agreement was announced 7 days after the Canyon Agreement (RootsRX execution date of 9/5/19, 8K post date of 9/6/19) so I am thinking we should hear the outcome any day...and likely tomorrow. I am feeling like it is unlikely to happen...and that the drop from $1.25 to $1.14, yesterday, was my confirmation.
Finally putting investing on the backburner and getting back to video games? j/k.
Thanks for sharing!
That is exactly what it is Hoop! He sees it for the adolescent industry that it currently is, knowing all well what it could potentially become, but evaluating based on reality and not future expectation. Albeit the shareprice is not where current shareholders want it to be, his business sense is securing shareholder value for years to come. Not to mention, the company is currently on pace to do double the revenue Medicine Man has historically ever done...and that is without Starbuds.
Under your rationale the same could be said about Terry Booth, Cam Battley, Vic Neufeld, Mike Gorenstein and Bruce Linton. If you recall, Andy justified his acquisition terms based on the values/multipliers being used by the other Canadian companies in the industry. The same Canadian companies that have also fired their old executives leaving the new replacements in charge to clean up their books by selling off assets for HUGE losses...because they were absolutely terrible appraisal/valuations. (For example: Aurora bought Whistler Medical for $175M...a company that brought in an annual revenue of $12M...meaning ROI would have taken roughly 15 years!) As much as I was blinded at the time and bought into the "family man" persona that Andy pushed, in my opinion, the delay in Colorado legislation turned out to be the best thing for Medicine Man. It allowed the greedy Canadian companies to show their true cards...reminding everyone that they bought in based on emotion and the thought of getting rich quick...when the reality is Andy's former deals were probably along the same lines as the Canadian players. We aren't being told exactly why these deals have gone south. You continue to think it is because Andy is no longer in the picture. I think you are right...to an extent. After Justin Dye's ACTUAL due diligence...Andy's CUSHY deals are no longer in the picture. The term sheet expiration is just the business polite way of saying we couldn't come to an agreement, without pointing fingers. (Aside from Albert Gutierrez's comments which essentially justified my point...that this company is going to be run as 'a Business', and not 'a family'.)
No need to reopen the RS win/lose/net neutral debate.
The RS could be anywhere from a 1-2 to a 1-30 with an endgame of getting the stock to a $4 uplist price. Obviously hoping that news would be released potentially raising the stock to a price where it is not necessary.
I think the confusion is in the interpretation of the 1-30 RS. From your numbers you understood it as they will pick 1-30, regardless or current share price. I took it as, and I could be wrong but it is how I remember reading it, that they approved the range because the end goal was a $4 share price. Meaning, the 1-30 would only apply if the stock was 1333cents. In your 19cents example the RS would be around 1-21.
Anyway, my whole basis was off my interpretation of the RS. If no news is released...or (perceived) negative news (like Altria)...knowing the RS goal is to get the stock to $4, right now there is no catalyst. Therefore if someone firmly believe that a 1-30 is the endgame then any buy in above the 1-30, or .1333cent level, is a loss. Which could also explain the limited amount of buying at this level.
I am gonna have to force myself to quit watching this. Almost 128K shares at 19cents...completely ridiculous.
100K shares available in the under 20cent range. I guess when they announced that 'it could be' a 30for1, which puts the stock around the 13cent level, people arent interested unless it is below that. I guess the consensus is, why buy now and lose twice (share count and post RS account value...if your avg share price is above the RS benchmark) when you can buy under the 13cents and win....or if you miss out just wait until after. I guess the gamble is whether or not there will be significant news to move the stock....which by the number of shares available...they must think there isnt.
As at August 31, 2020, we had a working capital surplus of $1,700,044 and cash on hand of $1,293,749. We estimate our minimum necessary expenses for the year to be roughly $2.5 million in which case we would require
approximately $1.2 million in additional financed cash to meet our minimum level of expenditures. These necessary expenses include professional fees, wages and general and administrative expenses necessary to satisfy our public reporting requirements.
During the next twelve month period (beginning September 1, 2020), we intend to:
· pursue a listing on a U.S. senior stock exchange or market;
· pursue technology out licensing opportunities for our patented DehydraTECH technology. This will be focused first primarily on the CBD-from hemp and nicotine sectors, and will evolve as time allows for completed R&D in other sectors, to the NSAID, and will eventually include the anti viral drug sectors if and as our R&D supports such initiatives;
· identify and secure sources of equity and/or debt financing for intellectual property pursuit and maintenance, R&D, and consumer product
formulation and marketing and general corporate operations;
Thanks Abundance. That was a good listen. Very down to earth.
I would agree. The Big Pharma area is exciting. Nicotine was exciting when Dr. Gottlieb was the Deputy Commissioner of the FDA. He was the one pushing the tobacco industry toward smokeless nicotine. I feel like it is only a matter of time before public sentiment catches up to where he was trying to force the industry. We all know CBD is widely popular...and regulation has yet to really make up their mind in this area. Once that happens, the larger companies are going to want to take advantage of consumer interest. LXRP will be sitting ready to go with its patent portfolio and VAST research in CBD/cannabis. The oil/water/smell thing is a big deal. The same can be said once cannabis gets to the point of legalization...and therefore increased regulation (in the US). It is hard to understand that we are only at the tip of the iceberg. With social media people are becoming more informed. They are also becoming a more health conscious. I think it is just a matter of time (years...not days or months) before the general public forces the larger companies of yesterday to move toward heathier/safer/quicker options and when that time comes hopefully they will be forced to turn to LXRP because LXRP will already have locked down the solution.
They were. I didn't like the phrasing. My concern is when effective therapies are determined to be a solution...and if they fall in the DehydraTECH category...they aren't going to be showing up knocking on the door with a solution. They won't be saying "look what DehydraTECH can do for you". They will show up saying, "we think this is what DehydraTECH CAN DO...and if you give us money we will then go and research it...and if it IS WHAT we think DehydraTECH is capable of doing we will report back with evidence...and if you want to use it as part of your process we will give you "exclusivity".
When I heard the way that it was phrased...the only thing that I thought was, "oh great, more research".
Lexaria has claimed that their license fee is easily offset by the (lower) drug (dosage) savings that the Licensing company needs to use in order to get the same bioavailability results.
Obviously Gilead is not forced into using DehydraTECH, but if you are Gilead, and you can only produce X amount of the drug, as an injection, per month...and your goal is to increase your production so that you could serve 10 or 100 times that X amount per month...it is easy to argue that pairing the drug with DehydraTECH is a no-brainer.
(1)Now you only need a fraction of the drug to accomplish the same amount of bioavailability.
(2)Since less drug involved, the overall price/expense to produce decrease...which we as the consumer probably won't see...but it will increase their margin.
(3)You are able to turn an injection into a pill format...which not only increases the shelf-life of the drug but also makes it easier to disburse among the population.
(4)You get to use a patented technology where there is documentation on file that pairing with this tech does not alter the drug that it is carrying...meaning you get to use the tech without the need, expense, and time of having your drug/solution re-evaluated by the FDA.
My problem was...when Lexaria talked about an anti-viral "solution"...they didn't! They played it as RESEARCH. They said, "once effective therapies are found, Lexaria COULD INVESTIGATE transforming the formula into an oral delivery format".
LEXY's PR agencies are finally trying to bounce this back:
https://virtual-strategy.com/2020/10/13/lexaria-bioscience-advances-antiviral-research-initiative-using-dehydratech/
I believe in the tech and I am doing the same. At this point O'Hashi was right, this is a stock you buy and hold for your kids and grandkids...
I am trying to remain hopeful that there is still something in the works between Altria and Lexaria, but say there isnt and Altria wants to sever its ties completely with DehydraTECH, how would that work if Altria buys out Cannadips? Do they have to honor the 10 year licensing agreement...or whatever timeframes may be left if/when the buyout occurs? If they dont, I sure hope there is something in the agreement that requires Altria to buyout the time remaining on the Cannadips/DehydraTECH license.
"The licensing agreement provided by Lexaria grants Cannadips Cannabis exclusive rights for this product format for the US market for 10 years; an option to expand the licence to Europe, Mexico and/or Canada; and contains minimum performance provisions in order to maintain exclusivity."
I misread your post...and corrected....however it has me thinking maybe I should sell all my shares for a loss and then buy back more if/when it hits 0.13/0.14.
I joined the bid side at 0.20 it went at 0.1976. Someone wants out. Feels like tomorrow might be more of the same.
100K bid at 0.20...will it get there? Will we see two negative days given that the Canadian market doesn't have the opportunity to sell today?
Apparently now we have a seller/buyer stalemate. The finra page does not list LXRP as halted.
And with how stringent Texas is when it comes to cannabis laws...and I doubt that they have plants to change anytime soon. Nice state to bump up against.
I just like Peter's play on words.
"feel it SOONER"...love it!
no argument with that...
So two more of Andy Williams potential acquisitions to either complete or allow their term sheets to lapse. I am assuming that they will probably let both run out...before they make the Starbuds announcement. I mean, why allow previous bad business decisions taint your biggest business/stock catalyst? It makes more sense to allow the stock to take the hit until these two eventually fail...and then counter with your new ERA of the company.
...but exclusivity in North America is HUGE when their biggest competitor also happens to be "researching" the same technology.
"Altria's revenue, excluding excise taxes, dipped 1% in 2019. Its adjusted shipments of cigarettes, which exclude trade inventory movements and other factors, fell 7% due to the overall industry's decline and retail share losses to rival brands.
Its total share of the domestic retail cigarette market dipped from 50.2% in 2018 to 49.7% in 2019, as Marlboro, its premium brands, and discount brands all posted year-over-year declines. That pressure indicates that Altria's biggest domestic rival, British American Tobacco's (NYSE:BTI) Reynolds American, is gaining ground with U.S. smokers."
https://www.fool.com/investing/2020/10/05/is-altria-stock-a-buy/
The manipulation of this stock drives me crazy....and even more so on day after the time I buy.
Welcome!...with massive potential comes massive frustration...but you will find that the existing members of this board are extremely knowledgeable, follow all new releases by the company and/or have a fast track to getting their questions/emails answered by the man in charge.
I hope I am wrong...and I keep adding to my position assume that I am wrong...however my gut feels like LXRP will extend the deadline based on request by Altria. I just think that Altria will request the deadline be moved and entice them with a future agreement with cannabis.
I try to reason myself away from these thoughts however the amount of shares available under 0.30USD just makes no sense for what potentially could happen in the next few days, that is, unless it doesn't (or is delayed).
I listened to the April podcast, more on their product, nothing on the technology...but they are excited and focused on getting a license in New Jersey. I am in the middle of an hour and a half podcast with Peter from July 2019. So far nothing about the tech but Peter is getting into specifics surrounding each products on the market (name selection and ingredients). This company is definitely just getting started. Good days ahead for sure!
Overall, I thought it was an interesting interview. You can speed the podcast onto 1.2x the speed and it will sound normal. (9min mark to about 11:15) Comparing his tech talk in this interview with the others that I have listened to...he does a good job talking about the tech, mentioning that he licenses 'the patented technology', and giving it pharmaceutical based roots...even though he never does mention Lexaria by name...just calls it 'a Canadian biosciences company' (twice).
Cannabis Economy podcast interviewed Peter Barsoom in 2017 and then again this past March. I think I remember the recent one, where he considered the technology, his technology...it annoyed me at the time because there was no mention of Lexaria whatsoever. I get it now...it's a licensed technology you don't want to tell your competition. I searched Spotify, because I was gonna listen again, and I can see that (it's not Cannabis Economy but) there are two newer podcasts available. One from April and another from late August. I think tomorrow I will give, at least, the August one a listen:
https://open.spotify.com/episode/0jXl8vPU2IVErsLL06jQGt?si=MQbKSOk_S7SuWhQbj4sbuQ
That's a good catch! I am glad you attached the article because I couldn't find anything through Google search. I know earlier this year Chris mentioned that they would be expanding into multiple states and expected to see revenue increase by almost tenfold. Lexy and 1906 have an odd relationship when it comes to recognizing the technology. Outside of the bottom of their website 1906 just doesn't do it. I figure it is what was negotiated in their contract and due to 'competitive advantage'. Probably also why Lexy didnt make an announcement.
There are 100K shares available at 0.26...right now it is a buyers market. No need to jump up just yet. If you have a competitive bid...it is just a matter of time before it comes to you. Especially later in the day and going into the weekend.
I see what you are saying...and I know we discussed it on this board. Do you think that they have come far enough or do you think that there will be an amendment to the current (LXRP) contract to extend it until all the assets are ready?
You right. It doesn't make sense that they let it drag out especially since there has been multiple articles recently that the major focus of the lead tobacco suppliers is non-combustible...because that is where their sales are increasing...and that they have been seeing consistent decline in cigarette sales YoY. Are you hinting that this constant dump might be them (or someone close to them) bailing out before the deadline...because they plan on letting the agreement lapse?
Yes we did...and yes we do.
It's official, Medpharm split from Schwazze.
https://www.biospace.com/article/releases/medpharm-officially-splits-from-schwazze/
If he got scammed, which you continue to insist happened, then why did it take so long for him to step down as an advisor? A person of his "status" would have bailed the second he realized he was swindled. He doesn't do charity work. The fact that he stayed so long, after this turned into a crap show. I am guessing he only did it expecting a payday...so he orchestrated the RS with the expectation of this hitting $20/share so his "signing bonus" kicked in. Sounds ethical to me.
Wow DrugDoctor, that's awesome. Been doing the same but still over $2.
Right...and I am not sure what time they actually presented...or will present.